IDEXX Laboratories, Inc.
corporate_fare Company Profile
IDEXX Laboratories, Inc. (NASDAQ:IDXX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for IDXX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for IDXX spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- IDEXX 10-Q Details Q3 EPS of $4.01, $934M Nine-Month Net Income and $250M CoVetAI Deal
- IDEXX Lifts Full-Year Outlook as Diagnostics Demand Offsets 1.8% Drop in Vet Visits; Shares Jump 19%
- IDEXX Beats on Q3 Revenue, Raises Full-Year EPS Outlook to $14.96-$15.16
- IDEXX Posts $4.01 Third-Quarter EPS
- IDEXX Acquires CoVetAI to Boost Veterinary Workflow Intelligence
Financial Snapshot
Short Interest & Short Volume
4.45 days to coverFINRA reported short interest of 2,354,117 shares in IDXX as of the October 30, 2026 settlement, a 22.0% increase from the prior period — about 4.5 days to cover at its recent average daily volume. On November 20, 2026, 50.2% of IDXX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.